Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-11-01

Clinical Trial Update: Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Belsomra at 10 mg and 20 mg to placebo in non-elderly adults with insomnia completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Belsomra (suvorexant)

Snippet

Sponsor: Henry Ford Health System | Conditions: Insomnia | Phase 4 | Status: COMPLETED | Results posted: 2019-11-01